Table 2.
Factors associated with an ultralow HIV-1 DNA level (<20 copies/106 PBMCs) at week 96
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |
| Sex | 0.100 | 0.092 | ||||
| Male | 1.00 | 1.00 | ||||
| Female | 2.42 | (0.85–6.93) | 3.40 | (0.82–14.15) | ||
| Age (years) | 1.01 | (0.96–1.07) | 0.633 | |||
| Time from diagnosis to ART (months) | 0.98 | (0.94–1.01) | 0.183 | |||
| Transmission route | 0.857 | |||||
| Homosexual | 1.00 | |||||
| Heterosexual | 1.36 | (0.44–4.27) | ||||
| Others | 1.42 | (0.20–9.82) | ||||
| HIV-1 subtype | 0.717 | |||||
| AE | 1.00 | |||||
| B/C/BC | 1.48 | (0.37–5.96) | 0.584 | |||
| Others | 1.68 | (0.48–5.95) | 0.418 | |||
| ART therapy | 0.477 | |||||
| AZT/d4T + 3TC + NVP | 1.00 | |||||
| TDF + 3TC + EFV | 0.67 | (0.22–2.04) | ||||
| Plasma viral load at enrollment (log copies/mL) | 0.71 | (0.36–1.41) | 0.330 | |||
| HIV-1 DNA at enrollment (log copies/106 PBMCs) | 0.72 | (0.17–3.11) | 0.656 | |||
| CD4+ T-cell count at enrollment (cells/μL) | 1.00 | (1.00–1.01) | 0.134 | |||
| Nadir CD4+ T-cell count (cells/μL) | 1.00 | (1.00–1.01) | 0.129 | |||
| CD8+ T-cell count at enrollment (cells/μL) | 1.00 | (1.00–1.00) | 0.528 | |||
| CD4/CD8 ratio at enrollment | 1.19 | (0.95–1.48) | 0.124 | |||
| Plasma viral load at week 96 | 0.808 | |||||
| Undetectable | 1.00 | |||||
| Viremia | 0.75 | (0.07–7.66) | ||||
| CD4+ T-cell count at week 96 (cells/μL) | 1.00 | (1.00–1.00) | 0.709 | |||
| CD8+ T-cell count at week 96 (cells/μL) | 0.99 | (0.99–0.99)a | 0.018 | 1.00 | (0.99–1.00) | 0.462 |
| CD4/CD8 ratio at week 96 (per 0.1 increase) | 1.28 | (1.05–1.55) | 0.014 | 1.29 | (1.05–1.59) | 0.017 |
OR Odds ratio, CI confidence interval, ART Antiretroviral therapy, PBMCs Peripheral blood mononuclear cells
a, 0.993~0.999